MYGN (MYGN) revenue breakdown
By segment, Diagnostics is the largest at 93% of fiscal 2020 revenue; Other grew fastest, -2% a year over 4 years.
By product, Hereditary Cancer is the largest at 45% of fiscal 2025 revenue; Tumor Profiling grew fastest, 16% a year over 7 years.
Revenue by segment
Fiscal years, as MYGN reports them in its 10-K filings; fiscal 2020 total $639M.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | Share |
|---|---|---|---|---|---|---|
| Diagnostics | $692M | $679M | $690M | $789M | $594M | 93% |
| Other | $48M | $49M | $53M | $62M | $45M | 7% |
Revenue by product
Fiscal years, as MYGN reports them in its 10-K filings; fiscal 2025 total $824M.
| Products | 2017 | 2018 | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hereditary Cancer | — | — | $480M | $347M | — | $316M | $306M | $328M | $364M | $372M | 45% |
| Prenatal | — | — | $105M | $77M | — | $107M | $116M | $151M | $177M | $186M | 23% |
| Mental Health | — | — | $113M | $74M | — | $94M | $128M | $138M | $170M | $144M | 17% |
| Tumor Profiling | — | — | $43M | $48M | — | $121M | $129M | $136M | $126M | $122M | 15% |
| Molecular Diagnostic Testing | $679M | $690M | — | — | — | — | — | — | — | — | — |
| Molecular diagnostic revenues | — | — | — | — | $514M | — | — | — | — | — | — |
| Other revenue | $49M | $53M | $62M | $52M | $44M | — | — | — | — | — | — |
| Autoimmune | — | — | $48M | $39M | — | $28M | — | — | — | — | — |
| Other revenue | — | — | — | — | — | $24M | — | — | — | — | — |
| Other | — | — | $900,000 | $1M | — | — | — | — | — | — | — |
| Other | — | — | — | — | — | $500,000 | — | — | — | — | — |
| Autoimmune | — | — | — | — | — | — | $300,000 | — | — | — | — |
Revenue by region
Fiscal years, as MYGN reports them in its 10-K filings; fiscal 2025 total $824M.
| Regions | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| U.S. | $805M | $596M | $604M | $592M | $672M | $770M | $768M | 93% |
| RoW | $46M | $42M | $87M | $87M | $82M | $68M | $56M | 7% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MYGN.
Open MYGN in InvestinglyQuestions
Where does MYGN make its money?
In fiscal 2020, by segment: Diagnostics $594M, Other $45M.
From MYGN's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.